Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Prolong TM, a New Revolutionary First Line Treatment for Premature Ejaculation is Licensed in Europe

December 7, 2012

LONDON, December 7, 2012 /PRNewswire/ –

Prolong TM a revolutionary new treatment for premature ejaculation (PE)
[http://www.aboutpe.com/treatment-of-premature-ejaculation/prolong ], was peer reviewed
and presented today at the European Society for Sexual Medicine (ESSM) annual conference
in Amsterdam where it was recommended as first line treatment for premature ejaculation.

(Photo:
http://photos.prnewswire.com/prnh/20121207/582124 )

During independent clinical trials in two London Teaching Hospitals the Prolong TM
training programme was shown to be three times more effective and worked in 50% more men
than psychosexual therapy, (the then current gold standard treatment), and is at least
four to five times cheaper. The Prolong TM programme was not associated with any side
effects during trials.

Men with premature or early ejaculation [http://www.aboutpe.com ] were found to be
more sensitive to penile stimulation than those without. Dr Andy Zamar, the creator of
Prolong TM explained to delegates how Prolong TM works by repeated subthreshold
stimulation of the most sensitive parts of the penis producing a long term reduction of
this sensitivity. This effect is called habituation and is thought to be permanent.

Men who used the Prolong TM prototype with the programme in the clinical trials
improved by week one and reached maximal improvement by week six. The Prolong TM programme
trained men to last on average 11 times longer during intercourse by learning to control
their climax. The 11 fold improvement was maintained when they were reviewed three months
after they completed the programme. The Prolong TM programme was associated with increased
interest, initiative, frequency and satisfaction in intercourse.

Dr Zamar explains: “I wanted to design a programme to treat premature ejaculation
which would see men train on their own, and then carry this into having intercourse
without the need for or use of any other treatments such as anaesthetics or pills”.

At the conference, Dr Zamar reviewed a large study conducted in three countries (USA,
Italy and Germany) of 12,133 men aged 18-70 which found that premature ejaculation
afflicts 22.7% of men across all ethnic and age groups. Alarmingly the study found that
42% of men afflicted use alcohol and 16% use drugs, such as amphetamines, cocaine and
heroin or opiates to address the condition. Only 9% went to doctors to seek help and of
those 91.5% reported little or no improvement after seeking treatment. This study has
shown that effectively, less than 1% benefit from existing treatments and the great
majority of afflicted men use drugs and alcohol to address the condition risking major
health, social, professional and relationship damage.

Continuing, Dr Zamar said: “The fact that men can purchase Prolong TM discreetly and
train on their own, and the very large effect size compared to any other clinically
trialled treatment for premature ejaculation, as well as the long term sustained benefits,
means that Prolong TM should be used by any man as a first line if they wish to gain
better control over climax.”

The relatively low cost of the programme compared to other available treatments
[http://www.aboutpe.com/treatment-of-premature-ejaculation/comparison-chart-for-pe-treatments ]
(200 Euros for the six week training programme compared to 1000-3000 Euros for
psychosexual therapy, 26.50 Euros per pill for Dapoxetine (Priligy) every time men have
intercourse and local anaesthetics which have to be used for life), offers an additional
advantage to Prolong TM being recommended as a first line treatment for premature or early
ejaculation.

Prolong TM was made available for sale in Europe at http://www.aboutpe.com after
the European regulatory authorities reviewed the clinical data as well as the safety
profile and manufacturing standards and licensed Prolong TM for Climax control training in
the 30 countries of the EEA as a non prescription item. Applications to the FDA and
Canadian Medical Device Licence for approval in the USA and Canada are underway.

For further information on Prolong TM, please visit: http://www.aboutpe.com


    Photo: 

http://photos.prnewswire.com/prnh/20121207/582124

SOURCE freud communications


Source: PR Newswire